GH1 T1663A polymorphism and cancer risk: a meta-analysis of case–control studies
- 195 Downloads
Many studies have demonstrated that the most common polymorphism (T1663A, rs2665802) in the promoter region of growth hormone 1 (GH1) gene might play an important role in cancer development and progression. This meta-analysis aims to investigate a more precise estimation of the relationship between GH1 T1663A polymorphism and cancer risk. We searched CISCOM, CINAHL, Web of Science, PubMed, Google Scholar, EBSCO, Cochrane Library, and CBM databases from inception through October 1st, 2013. Meta-analysis was performed using the STATA 12.0 software. Seven studies were included with a total of 4,018 cancer patients and 5,308 healthy controls. Our meta-analysis results revealed that GH1 T1663A polymorphism was associated with increased cancer risks. Subgroup analysis by cancer type showed significant associations between GH1 T1663A polymorphism and increased colorectal cancer risk, but there was no evidence of any association with breast cancer. Further subgroup analysis based on ethnicity indicated that GH1 T1663A polymorphism might increase cancer risks among Asian populations. However, no statistically significant association was found among Caucasian populations. Meta-regression analyses also suggested that cancer type and ethnicity may be the main sources of heterogeneity. No publication bias was detected in this meta-analysis. The present meta-analysis indicates that GH1 T1663A polymorphism may contribute to the risk of colorectal cancer, especially among Asian populations.
KeywordsCancer Growth hormone 1 Single nucleotide polymorphism Susceptibility Meta-analysis
We thank all our colleagues working in the Department of Medical Oncology, the First Hospital of China Medical University. This work was supported by a grant from the Scientific Research Project Foundation of Liaoning Provincial Education Department (no. 05L570). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Conflicts of interest
- 15.Jia YB, Zhang JZ, Bao XQ, Yan Y. Relationship between a polymorphism in the growth hormone1 gene and gastric cardia adenocarcinoma. J Baot Med Coll. 2008;24(6):555–6.Google Scholar
- 21.Gong JP, Gao CM, Takezak T, Wu JZ, Ding JH, Liu YT, et al. Relationship between growth hormone 1 genetic polymorphism and smoking, alcohol drinking and the susceptibility of colorectal cancer. China J Cancer Prev Treat. 2006;13(15):1134–7.Google Scholar
- 23.Filopanti M, Olgiati L, Mantovani G, Corbetta S, Arosio M, Gasco V, et al. Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab. 2012;97(2):E165–72.CrossRefPubMedGoogle Scholar
- 26.Jia YB, Zhang JZ, Wang Q. Association study of single nucleotide polymorphism in the growth hormone 1 gene and esophageal cancer. J Baot Med Coll. 2008;24(4):335–7.Google Scholar
- 27.Jia YB, Zhang JZ, Bao XQ, Yan Y. Relationship between a polymorphism in the growth hormone1 gene and gastric cardia adenocarcinoma. J Baot Med Coll. 2008;24:555–6.Google Scholar
- 29.Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Boillot C, et al. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2316–25.CrossRefPubMedGoogle Scholar